60 Degrees Pharmaceuticals(SXTP.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
60 Degrees Pharmaceuticals
SXTP.US
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. It offers Arakoda for malaria prevention treatment. The company also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal and pneumocystis pneumonias, and candidiasis disease; and Celgosivir for Zika, respiratory viruses, and dengue fever. It also has patent license agreement with Tufts Medical Center to jointly advance the development and commercialization of tafenoquine for the treatment and prevention of babesiosis.
4.622 T
SXTP.USMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
B
PharmaceuticalsIndustry
Industry Ranking32/190
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE158.62%A
    • Profit Margin-576.30%E
    • Gross Margin47.12%B
  • Growth ScoreA
    • Revenue YoY63.89%A
    • Net Profit YoY24.69%B
    • Total Assets YoY13.14%B
    • Net Assets YoY17.76%A
  • Cash ScoreB
    • Cash Flow Margin98.85%C
    • OCF YoY63.89%A
  • Operating ScoreD
    • Turnover0.21D
  • Debt ScoreB
    • Gearing Ratio29.85%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    60 Degrees Pharmaceuticals 1Q 2026: Revenue $162.09K, EPS ($1.28) — 10-Q Summary

    TradingView·
    US
    SXTPW
    -0.50%
    US
    SXTP
    +3.60%
    US
    GDRX
    +2.88%
    TradingView·
    US
    SXTPW
    -0.50%
    US
    SXTP
    +3.60%
    US
    GDRX
    +2.88%

    60 Degrees Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 162.09 K

    Earnings Watch·
    US
    SXTP
    +3.60%
    Earnings Watch·
    US
    SXTP
    +3.60%

    60 Degrees Pharmaceuticals Announces First Quarter 2026 Results | SXTP Stock News

    StockTitan·
    US
    SXTP
    +3.60%
    US
    BIB
    -3.74%
    US
    SBIO
    -3.43%
    StockTitan·
    US
    SXTP
    +3.60%
    US
    BIB
    -3.74%
    US
    SBIO
    -3.43%

    SXTP Q1'26 Earnings: EPS estimate is (0.76) USD

    TradingView·
    US
    SXTP
    +3.60%
    US
    XBI
    -2.31%
    US
    PBE
    -0.58%
    TradingView·
    US
    SXTP
    +3.60%
    US
    XBI
    -2.31%
    US
    PBE
    -0.58%

    60 Degrees Pharmaceuticals shares are trading higher. The company reported its Q4 financial results.

    benzinga_article·
    US
    BIB
    -3.74%
    US
    SXTPW
    -0.50%
    US
    LABU
    -6.92%
    benzinga_article·
    US
    BIB
    -3.74%
    US
    SXTPW
    -0.50%
    US
    LABU
    -6.92%
    © 2026 Longbridge｜Disclaimer